Literature DB >> 6360867

A decade of progress in the management of hypertension.

M Moser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6360867     DOI： 10.1161/01.hyp.5.6.808

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  8 in total

1.  The costs of treating hypertension.

Authors:  M Moser
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 2.  The large studies in hypertension: what have they shown?

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

Review 3.  Prehypertension--prevalence, health risks, and management strategies.

Authors:  Brent M Egan; Sean Stevens-Fabry
Journal:  Nat Rev Cardiol       Date:  2015-02-17       Impact factor: 32.419

4.  Effect of repeated measurements of blood pressure on blood pressure in essential hypertension: role of anxiety.

Authors:  A McGrady; J T Higgins
Journal:  J Behav Med       Date:  1990-02

5.  Liver drug metabolism and blood pressure response to a lipophilic and hydrophilic beta blocker.

Authors:  S Säkö; E A Sotaniemi; M Anttila
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

Review 6.  Prehypertension: risk stratification and management considerations.

Authors:  Brent M Egan; Stevo Julius
Journal:  Curr Hypertens Rep       Date:  2008-10       Impact factor: 5.369

Review 7.  Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.

Authors:  Daniel T Lackland; Edward J Roccella; Anne F Deutsch; Myriam Fornage; Mary G George; George Howard; Brett M Kissela; Steven J Kittner; Judith H Lichtman; Lynda D Lisabeth; Lee H Schwamm; Eric E Smith; Amytis Towfighi
Journal:  Stroke       Date:  2013-12-05       Impact factor: 7.914

Review 8.  Historical perspectives on the management of hypertension.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-08       Impact factor: 3.738
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.